NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Inventiva S.a. IVA
7 fiscal years on record · EUR · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
€9.2M
▼ 47.4% vs FY2023
EPS · FY24
€-3.08
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-2002.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 9.2M
Revenue, FY2024 · full 7-year series below
Revenue
Net income
The company lost 2003 cents on every revenue dollar this year.
Per share
EUR -3.08
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-1060.6%
Net margin-2002.7%
Return on assets-195.4%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+29.9%
+5.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 119.0M
total assets, end of FY2024
Total assetsEUR 119.0M
CashEUR 96.6M
Current ratio0.92×
History
7 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2024
2023
2022
2021
2020
2019
2018
Revenue €B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income €B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA €B
·
·
·
·
·
·
·
Income tax €B
0.0
0.0
−0.0
0.0
0.0
0.0
·
Net income €B
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted €
−3.08
−2.43
−1.31
−1.27
−0.99
−1.28
·
Dividend / sh €
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
Shares out B
0.10
0.05
0.04
0.04
0.04
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
20 of 20
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed